DelveInsight’s “Schizophrenia – Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Schizophrenia, historical and forecasted epidemiology as well as the Schizophrenia market trends in the United States, the EU4(Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Schizophrenia Key Highlights
-
The Key Companies working in Schizophrenia market includes Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Reviva Pharmaceuticals and many others.
-
The Key Therapies included in Schizophrenia market includes Brexpiprazole, Aripiprazole, Cariprazine, Bifeprunox, CTP-692, Luvadaxistat and many others
Schizophrenia Overview
Schizophrenia is a serious mental disorder in which people interpret reality abnormally. Schizophrenia may result in some combination of hallucinations, delusions, and extremely disordered thinking and behavior that impairs daily functioning, and can be disabling.
Schizophrenia is a complex, chronic mental health disorder characterized by an array of symptoms, including delusions, hallucinations, disorganized speech or behavior, and impaired cognitive ability. The early onset of the disease, along with its chronic course, make it a disabling disorder for many patients and their families.Disability often results from both negative symptoms (characterized by loss or deficits) and cognitive symptoms, such as impairments in attention, working memory, or executive function.In addition, relapse may occur because of positive symptoms, such as suspiciousness, delusions, and hallucinations.The inherent heterogeneity of schizophrenia has resulted in a lack of consensus regarding the disorder’s diagnostic criteria, etiology, and pathophysiology.
Schizophrenia Epidemiology Insights
-
The prevalence of schizophrenia is between 0.6% and 1.9% in the U.S. population. Moreover, a claims analysis has estimated that the annual prevalence of diagnosed schizophrenia in the U.S. is 5.1 per 1,000 lives.
-
The prevalence of the disorder seems to be equal in males and females, although the onset of symptoms occurs at an earlier age in males than in females. Males tend to experience their first episode of schizophrenia in their early 20s, whereas women typically experience their first episode in their late 20s or early 30s.
Click here to learn more about the Schizophrenia Market Landscape.
The Report Covers the Schizophrenia Epidemiology Segmented by:
-
Total Schizophrenia incident cases
-
Total Schizophrenia prevalent cases
-
Total Schizophrenia treatment cases
-
Total Schizophrenia diagnostic cases
Schizophrenia Market Outlook
With no cure for schizophrenia, the main goals of schizophrenia treatment include symptom targeting and prevention of relapsed cases. Schizophrenia requires lifelong treatment, even when symptoms have subsided. Treatment with medications and psychosocial therapy can help manage the condition. In some cases, hospitalization may be needed. Pharmacological therapy plays a vital role in treating this disease, where many mono and combination pharmacological therapies are available for treating schizophrenia symptoms. Antipsychotics are the first choice among psychotropic agents used to treat schizophrenia. For some patient groups, treatment strategies include a combination of neuroleptics and antiepileptics. Second-generation antipsychotic (SGAs) medications are generally preferred because they pose a lower risk of serious side effects than first-generation antipsychotics (FGAs). The FGAs have frequent and potentially significant neurological side effects, including the possibility of developing a movement disorder (tardive dyskinesia) that may or may not be reversible.The treatment options for schizophrenia include medication (antipsychotics), psychological counseling and social support, cognitive behavioral therapy, and electroconvulsive therapy (ECT). Currently available antipsychotics, which are thought to work primarily via modulation of dopamine, largely target positive symptoms. As a result, many patients are left with residual negative and cognitive symptoms. New research combined with an increased understanding of the etiology and pathophysiology of schizophrenia is leading to the development of novel agents to improve schizophrenia management and address the above-mentioned gaps.
According to DelveInsight, the Schizophrenia market in 7MM is expected to witness a major change in the study period 2019–2032.
Key Companies Working in the Schizophrenia Market
-
Boehringer Ingelheim
-
Karuna Therapeutics
-
Acadia Pharmaceuticals
-
Reviva Pharmaceuticals
-
Sunivion/PsychoGenics/Otsuka Pharmaceuticals
-
Neurocrine Biosciences/Takeda
-
Minerva Neurosciences
-
Newron Pharmaceuticals
-
Lyndra Therapeutics
And many others
Schizophrenia Therapies Covered and Analyzed in the Report:
-
Brexpiprazole
-
Aripiprazole
-
Cariprazine
-
Bifeprunox
-
CTP-692
-
Luvadaxistat
-
APN1125
-
ITI-214
-
Risperidone
And many others
Learn more about the Key Companies and Emerging Therapies in the Schizophrenia Market.
Table of Contents
-
Key Insights
-
Schizophrenia Introduction
-
Executive Summary of Schizophrenia
-
Disease Background and Overview
-
Epidemiology and patient population
-
Schizophrenia Emerging Therapies
-
Schizophrenia Market Outlook
-
Market Access and Reimbursement of Therapies
-
Market Drivers
-
Market Barriers
-
Appendix
-
Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
Learn about the detailed offerings of the report @ Schizophrenia Market Outlook.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services